A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy

被引：3
作者：
Ciombor, Kristen Keon
Edenfield, William Jeffery
Hubbard, Joleen Marie
O'Dwyer, Peter J.
Becerra, Carlos
Larson, Tim
Spira, Alexander I.
Grothey, Axel
Manoharan, Divya
Li, Wei
Li, Youzhi
Borodyansky, Laura
Li, Chiang
Bekaii-Saab, Tanios S.
机构：
[1] Ohio State Univ Wexner Med Ctr, Columbus, OH USA
[2] Univ Med Ctr, Greenville Hosp Syst, Inst Translat Oncol Res, Greenville, SC USA
[3] Mayo Clin, Rochester, MN USA
[4] Hosp Univ Penn, Philadelphia, PA 19104 USA
[5] US Oncol Res, TOPS Phase Program 1, Dallas, TX USA
[6] US Oncol Res, TOPS Phase Program 1, Minneapolis, MN USA
[7] US Oncol Res, Virginia Canc Specialists Res Inst, Fairfax, VA USA
[8] Boston Biomed Inc, Cambridge, MA USA
[9] Ohio State Univ Comprehens Canc Ctr, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3617
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
    Elena Elez
    Carles Pericay
    Manuel Valladares-Ayerbes
    Inmaculada Bando
    Maria Jose Safont
    Javier Gallego
    Cristina Grávalos
    Antonio Arrivi
    Alfredo Carrato
    Verónica Conde
    Maria José Ortiz
    Carlos López
    Beatriz Alonso
    Inmaculada Ruiz de Mena
    Eduardo Díaz-Rubio
    Josep Tabernero
    Enrique Aranda
    British Journal of Cancer, 2019, 121 : 378 - 383
  • [43] A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
    Elez, Elena
    Pericay, Caries
    Valladares-Ayerbes, Manuel
    Bando, Inmaculada
    Safont, Maria Jose
    Gallego, Javier
    Gravalos, Cristina
    Arrivi, Antonio
    Carrato, Alfredo
    Conde, Veronica
    Jose Ortiz, Maria
    Lopez, Carlos
    Alonso, Beatriz
    Ruiz de Mena, Inmaculada
    Diaz-Rubio, Eduardo
    Tabernero, Josep
    Aranda, Enrique
    BRITISH JOURNAL OF CANCER, 2019, 121 (05) : 378 - 383
  • [44] MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF
    Mosakhani, Neda
    Lahti, Leo
    Borze, Ioana
    Karjalainen-Lindsberg, Marja-Liisa
    Sundstrom, Jari
    Ristamaki, Raija
    Osterlund, Pia
    Knuutila, Sakari
    Sarhadi, Virinder Kaur
    CANCER GENETICS, 2012, 205 (11) : 545 - 551
  • [45] Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
    Becerra, Carlos
    Stephenson, Joe
    Jonker, Derek J.
    Cohn, Allen Lee
    Asmis, Timothy R.
    Bekaii-Saab, Tanios S.
    Conkling, Paul R.
    Garbo, Lawrence E.
    Lenz, Heinz-Josef
    Richards, Donald A.
    Spira, Alexander I.
    Mikhail, Sameh
    Goodwin, Rachel Anne
    Yoon, Harry H.
    Hume, Stephanie
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Study 20050203/PRIME - Effect of Post-Progression Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody (mAb) Therapy In Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC)
    Siena, S.
    Douillard, J. Y.
    Cassidy, J.
    Tabernero, J.
    Burkes, R.
    Barugel, M. E.
    Humblet, Y.
    Cunningham, D.
    Yu, H.
    Krishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S435 - S435
  • [47] Phase II study of tivantinib (ARQ 197) and cetuximab in patients with EGFR inhibitor-resistant, MET-High, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC)
    Lorenza, Rimassa
    Silvia, Bozzarelli
    Stefano, Cordio
    Filippo, Pietrantonio
    Laura, Toppo
    Sara, Lonardi
    Alberto, Zaniboni
    Roberto, Bordonaro
    Maria, Di Bartolomeo
    Wanda, Liguigli
    Vittorina, Zagonel
    Chiara, Tronconi Maria
    Luca, Di Tommaso
    Laura, Giordano
    Armando, Santoro
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] A phase 1B study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT)
    Price, T. J.
    Pirc, L.
    Cooper, P.
    Tebbutt, N.
    Karapetis, C.
    Singhai, N.
    Townsend, A. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S549 - S549
  • [49] Phase 1b/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with FOLFIRI plus /- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).
    Bendel, Johanna C.
    Hubbard, Joleen Marie
    O'Neil, Bert H.
    Jonker, Derek J.
    Starodub, Alexander
    Peyton, James D.
    Pitot, Henry C.
    Halfdanarson, Thorvardur Ragnar
    Nadeau, Benjamin Rolland
    Zubkus, John D.
    Adesunloye, Bamidele
    Edenfield, William Jeffery
    Li, Youzhi
    Li, Wei
    Grothey, Axel
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).
    Peeters, Marc
    Kim, Tae Won
    Li, Jin
    Cascinu, Stefano
    Ruff, Paul
    Suresh, Attili Venkatasatya
    Thomas, Anne
    Tjulandin, Sergei
    Guan, Xuesong
    Hoang, Tien
    Hei, Yong Jiang
    Price, Timothy Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345